Immatics (IMTX) Free Cash Flow (2019 - 2025)
Immatics (IMTX) posted Free Cash Flow of -$67.2 million for Q4 2025, down 31.72% sequentially from -$51.0 million in Q3 2025, and down 10.64% YoY from -$75.2 million in Q4 2024.
Immatics (IMTX) Free Cash Flow (2019 - 2025) Analysis & Trends
Immatics has reported Free Cash Flow for 7 years, with the latest figure at -$67.2 million in Q4 2025.
- Quarterly Free Cash Flow fell 10.64% year-over-year to -$67.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$193.5 million (down 26.41% YoY) and the FY2025 annual result came in at -$192.1 million, down 25.23% from the prior year.
- Free Cash Flow eased to -$67.2 million in Q4 2025 per IMTX's latest filing, from -$51.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $121.8 million in Q1 2022 and troughed at -$67.2 million in Q4 2025.
- A 5-year average of -$17.2 million and a median of -$25.8 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow jumped 727.62% in 2022, then sank 841.82% in 2024.
- Over 5 years, Free Cash Flow stood at -$26.8 million in 2021, then sank by 54.43% to -$41.4 million in 2022, then soared by 169.58% to $28.8 million in 2023, then tumbled by 310.72% to -$60.7 million in 2024, then slipped by 10.64% to -$67.2 million in 2025.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$67.2 million, -$51.0 million, and -$42.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | -67.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -67.16 Mn |
| Dec 31, 2025 | -67.16 Mn |
| Sep 30, 2025 | -50.99 Mn |
| Sep 30, 2025 | -50.99 Mn |
| Jun 30, 2025 | -42.59 Mn |
| Jun 30, 2025 | -42.59 Mn |
| Mar 31, 2025 | -32.75 Mn |
| Mar 31, 2025 | -32.75 Mn |
| Dec 31, 2024 | -60.70 Mn |
| Dec 31, 2024 | -60.70 Mn |
| Sep 30, 2024 | -33.97 Mn |
| Sep 30, 2024 | -33.97 Mn |
| Jun 30, 2024 | -32.95 Mn |
| Jun 30, 2024 | -32.95 Mn |
| Mar 31, 2024 | -25.45 Mn |
| Mar 31, 2024 | -25.45 Mn |
| Dec 31, 2023 | 28.81 Mn |
| Dec 31, 2023 | 28.81 Mn |
| Sep 30, 2023 | -26.15 Mn |
| Sep 30, 2023 | -26.15 Mn |